4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Reaffirmed by Royal Bank of Canada
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Royal Bank of Canada in a report issued on Monday, Benzinga reports. They currently have a $25.00 price objective on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 40.06% from the company’s […]
More Stories
Analyzing Mercury General (NYSE:MCY) & Deep Yellow (OTCMKTS:DYLLF)
Volatility & Risk Mercury General has a beta of 0.87, indicating that its stock price is 13% less volatile than...
Analyzing Mercury General (NYSE:MCY) & Deep Yellow (OTCMKTS:DYLLF)
Volatility & Risk Mercury General has a beta of 0.87, indicating that its stock price is 13% less volatile than...
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research...
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research...
VR Resources (CVE:VRR) Trading Down 16.7% – Here’s What Happened
VR Resources Ltd. (CVE:VRR – Get Free Report)’s share price traded down 16.7% during trading on Friday . The company...
VR Resources (CVE:VRR) Trading Down 16.7% – Here’s What Happened
VR Resources Ltd. (CVE:VRR – Get Free Report)’s share price traded down 16.7% during trading on Friday . The company...